Alt5 Sigma CORP 8-K filings

ALT5 Sigma Corporation announced the acquisition of Mswipe, a multi-currency payment card service, alongside reporting record first-quarter 2025 fintech revenues and positive strategic outlook.

ALT5 Sigma Corporation announced the appointment of seasoned financial executive David Danziger to its Board of Directors, who will also chair the Audit Committee, following the passing of long-serving director Richard Butler.

ALT5 Sigma Corporation has announced the prospective leadership and advisory team for Alyea Therapeutics Corporation, its healthcare asset slated for formal separation, featuring highly experienced professionals in pain management, drug development, and biotech commercialization.

ALT5 Sigma Corporation announces June 2, 2025, as the record date for the formal separation of its healthcare assets, Alyea Therapeutics Corporation.

ALT5 Sigma Corporation announces record first quarter 2025 results and the acquisition of Mswipe, expected to be immediately accretive to revenue and EBITDA upon closing.

ALT5 Sigma announces record Q4 revenue of $5.4 million and surpasses 1,000 customers, marking a significant milestone in its fintech growth.

ALT5 Sigma Corporation reports successful shareholder votes at its Annual General Meeting, including the re-election of board members and approval of a strategic spin-off of its healthcare assets.

ALT5 Sigma Corporation has signed a non-binding term sheet to acquire Soin Bioscience LLC, a pharmaceutical development company, through its subsidiary Alyea Therapeutics Corporation.

ALT5 Sigma Corporation announced record third-quarter revenue of $4.94 million, driven by strong performance in its fintech segment and increased customer onboarding.

ALT5 Sigma Corporation has appointed Peter Tassiopoulos as its new Chief Executive Officer, effective September 16, 2024, while Tony Isaac will transition to the role of President and remain Chairman of the Board.

ALT5 Sigma Corporation has entered into agreements to issue non-convertible debentures and warrants, raising up to $1.6 million in debt financing.

JanOne Inc. has officially changed its name to ALT5 Sigma Corporation and its Nasdaq ticker symbol to ALTS, effective July 15, 2024, to reflect its strategic shift towards fintech.

JanOne Inc. has entered into an agreement to sell up to $5 million of its common stock through an at-the-market offering.

JanOne Inc. has amended its previous 8-K filing to incorporate the financial statements of Alt 5 Sigma, Inc. and pro forma financial information following their merger.

JanOne Inc. has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, resolving a previous non-compliance notice.

JanOne Inc. has reached a settlement with the SEC, agreeing to pay a $250,000 civil penalty in quarterly installments.

JanOne Inc. has acquired Alt 5 Sigma, a fintech company, by issuing common and preferred stock, marking a significant expansion into blockchain-powered financial technologies.

JanOne Inc. has completed a registered direct offering, raising approximately $300,000 through the sale of units consisting of common stock and warrants to institutional investors.

JanOne Inc. received a notice from Nasdaq for failing to maintain the minimum required stockholders' equity of $2.5 million, putting its listing status at risk.

JanOne has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed at or above $1.00 for ten consecutive business days.

JanOne Inc. has entered into agreements with two investors to raise $600,000 through the sale of units, each consisting of common stock and a warrant.

JanOne Inc. amended its debt obligations with Isaac Capital Group and Live Ventures, adding convertibility features at a price of $0.61 per share and issuing new promissory notes.

JanOne Inc. has amended existing debt obligations and secured new financing totaling $600,000, all of which include the option to convert into common stock at a fixed price of $0.58 per share.

JanOne Inc. has agreed to repurchase outstanding warrants from an institutional investor for $250,000, effectively removing the potential for dilution from the exercise of these warrants.